MX2023007444A - Parapoxvirus modificado que tiene inmunogenicidad incrementada. - Google Patents
Parapoxvirus modificado que tiene inmunogenicidad incrementada.Info
- Publication number
- MX2023007444A MX2023007444A MX2023007444A MX2023007444A MX2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A MX 2023007444 A MX2023007444 A MX 2023007444A
- Authority
- MX
- Mexico
- Prior art keywords
- parapoxvirus
- modified parapoxvirus
- increased immunogenicity
- modified
- vector
- Prior art date
Links
- 241000700639 Parapoxvirus Species 0.000 title abstract 6
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24241—Use of virus, viral particle or viral elements as a vector
- C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un Parapoxvirus modificado, preferentemente un vector de Parapoxvirus, que tiene una inmunogenicidad incrementada, una célula biológica que contiene este Parapoxvirus modificado, una composición farmacéutica, preferentemente una vacuna, que contiene este vector de Parapoxvirus modificado y/o esta célula, y un nuevo uso de este Parapoxvirus modificado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20216198.0A EP4014991A1 (en) | 2020-12-21 | 2020-12-21 | Modified parapoxvirus having increased immunogenicity |
PCT/EP2021/085774 WO2022136033A1 (en) | 2020-12-21 | 2021-12-14 | Modified parapoxvirus having increased immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007444A true MX2023007444A (es) | 2023-07-03 |
Family
ID=73856481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007444A MX2023007444A (es) | 2020-12-21 | 2021-12-14 | Parapoxvirus modificado que tiene inmunogenicidad incrementada. |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP4014991A1 (es) |
JP (1) | JP2024500167A (es) |
KR (1) | KR20230122630A (es) |
CN (1) | CN117015609A (es) |
AR (1) | AR124384A1 (es) |
AU (1) | AU2021408377A1 (es) |
CA (1) | CA3202003A1 (es) |
CL (1) | CL2023001816A1 (es) |
CO (1) | CO2023008292A2 (es) |
IL (2) | IL303878A (es) |
MX (1) | MX2023007444A (es) |
TW (1) | TW202239428A (es) |
WO (1) | WO2022136033A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023233007A1 (en) * | 2022-06-02 | 2023-12-07 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Sars-cov-2 vaccines and uses thereof |
-
2020
- 2020-12-21 EP EP20216198.0A patent/EP4014991A1/en not_active Withdrawn
-
2021
- 2021-12-14 CA CA3202003A patent/CA3202003A1/en active Pending
- 2021-12-14 WO PCT/EP2021/085774 patent/WO2022136033A1/en active Application Filing
- 2021-12-14 MX MX2023007444A patent/MX2023007444A/es unknown
- 2021-12-14 IL IL303878A patent/IL303878A/en unknown
- 2021-12-14 AU AU2021408377A patent/AU2021408377A1/en active Pending
- 2021-12-14 CN CN202180085952.6A patent/CN117015609A/zh active Pending
- 2021-12-14 JP JP2023538065A patent/JP2024500167A/ja active Pending
- 2021-12-14 IL IL303876A patent/IL303876A/en unknown
- 2021-12-14 KR KR1020237024392A patent/KR20230122630A/ko unknown
- 2021-12-14 EP EP21836171.5A patent/EP4153231A1/en active Pending
- 2021-12-16 AR ARP210103524A patent/AR124384A1/es unknown
- 2021-12-17 TW TW110147377A patent/TW202239428A/zh unknown
-
2023
- 2023-06-19 CL CL2023001816A patent/CL2023001816A1/es unknown
- 2023-06-23 CO CONC2023/0008292A patent/CO2023008292A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022136033A1 (en) | 2022-06-30 |
JP2024500167A (ja) | 2024-01-04 |
IL303876A (en) | 2023-08-01 |
CN117015609A (zh) | 2023-11-07 |
AR124384A1 (es) | 2023-03-22 |
IL303878A (en) | 2023-08-01 |
CO2023008292A2 (es) | 2023-07-21 |
TW202239428A (zh) | 2022-10-16 |
CA3202003A1 (en) | 2022-06-30 |
KR20230122630A (ko) | 2023-08-22 |
AU2021408377A1 (en) | 2023-06-29 |
EP4153231A1 (en) | 2023-03-29 |
CL2023001816A1 (es) | 2024-01-12 |
EP4014991A1 (en) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
BR112017014060A2 (pt) | composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas | |
WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
WO2018143552A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
TW201612190A (en) | Flavivirus virus like particle | |
CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
CL2023001816A1 (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada | |
MX2023003199A (es) | Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5). | |
ZA202107428B (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
MX2022011077A (es) | Variantes de transglutaminasa. | |
MX2022002766A (es) | Vacunas contra el virus de la gripe y usos de las mismas. | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
MX2023007376A (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada. | |
WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
MX2020006476A (es) | Vacuna contra el virus de lassa. | |
MX2023007375A (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada. | |
NZ595060A (en) | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides | |
MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. | |
MX2023002080A (es) | Vector de poxviridae recombinante que expresa moleculas coestimuladoras. |